Incyte Corporation


SKU: INCY Category:


Incyte Corporation: Significant Clinical Progress in Pipeline Programs


Incyte Corporation’s 2023 earnings have been marked by the firm’s strong performance following a 14% increase in product and royalty revenues compared to 2022, reaching $3.7 billion. A significant milestone was achieved in the fourth quarter when total product and royalty revenue reached $1 billion for the first time. This growth has primarily been driven by the continued growth of Jakafi and the successful launch of Opzelura. In 2023, Jakafi’s net sales were $2.6 billion, representing an 8% increase compared to the prior year. The launch of Opzelura, underscored by new patient intake and refills in AD and vitiligo, generated robust growth of 162% to $338 million. Axatilimab has also been submitted to the FDA for approval, adding to the strength of the Jakafi and Opzelura sales, thus sprucing up the overall earnings for the company.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!